JSK Biomed (Co-CEOs Jinwoo Jeon and Jiheon Ma), a company specializing in aesthetic medical devices, announced on the 20th that its needle-free laser jet injector 'Mirajet' was selected as a finalist in the 'Lasers, Lights and Energy-Based Devices' category of the AMWC (The Aesthetic and Anti-Aging Medicine World Congress) 2026 Awards, a global medical aesthetics event.
The AMWC Awards are a prestigious awards ceremony that recognizes innovative clinical and industrial practices in the fields of beauty and anti-aging. The final winners will be announced at the Monaco ceremony on March 26th, following peer voting and judging by experts worldwide. JSK Biomed is the only Korean company nominated in this category.
MiraJet is the world's first laser-based pressure-assisted drug delivery system, delivering rapid, even injections of SkinBooster without a needle. Using microjet technology, it reduces procedure pain and recovery time while delivering precise drug delivery. It is considered the next-generation standard for medical aesthetics.
JSK Biomed is entering the major European and North American markets and strengthening its global clinical network by signing a global distribution agreement with Fotona, a leading Slovenian medical laser company, in 2025 to expand into the global market.
At AMWC 2026, JSK Biomed will operate a booth, and Dr. Park Jae-young of Apgujeong Oracle Dermatology will give a lecture on 'Needle-Free Jet Injection for Dermal Delivery' to share Mirajet's clinical usefulness and treatment know-how with experts from around the world.
A JSK Biomed official said, “The selection of AMWC Awards finalists and local lecture sessions will maximize the synergy of our global partnership,” and added, “We will elevate the status of K-medical aesthetics based on our unrivaled technological prowess.”
AMWC 2026 will be held for three days from March 26th at the GRIMALDI FORUM in Monaco.
- See more related articles
You must be logged in to post a comment.